TCGA-A7-A4SB-01A-21R-A266-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 14
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.180
- UV_RESPONSE_DN+0.160
- ESTROGEN_RESPONSE_EARLY+0.130
- CHOLESTEROL_HOMEOSTASIS+0.090
- ESTROGEN_RESPONSE_LATE+0.090
- WNT_BETA_CATENIN_SIGNALING+0.050
- APICAL_JUNCTION+0.030
- MITOTIC_SPINDLE+0.030
- NOTCH_SIGNALING+0.010
- TGF_BETA_SIGNALING+0.010
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.550
- INTERFERON_GAMMA_RESPONSE-0.480
- INTERFERON_ALPHA_RESPONSE-0.450
- INFLAMMATORY_RESPONSE-0.410
- OXIDATIVE_PHOSPHORYLATION-0.400
- COMPLEMENT-0.390
- IL6_JAK_STAT3_SIGNALING-0.360
- MTORC1_SIGNALING-0.360
- KRAS_SIGNALING_UP-0.350
- MYC_TARGETS_V1-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BSR_16_0051_A2_S82 | — | A | 0.849 |
| 2 | TCGA-A8-A09V-01A-11R-A034-07 | — | B | 0.845 |
| 3 | MNG660 | — | — | 0.823 |
| 4 | TCGA-A8-A0A4-01A-11R-A00Z-07 | — | A | 0.820 |
| 5 | SRR1311771 | GTEX | — | 0.815 |
| 6 | 3bc40056-88b6-483c-8701-747eb6e851c4 | — | — | 0.815 |
| 7 | SRR8613768 | — | E | 0.814 |
| 8 | TCGA-55-A494-01A-11R-A24X-07 | — | cohortA3 | 0.814 |
| 9 | TCGA-A7-A3IZ-01A-11R-A213-07 | — | B | 0.812 |
| 10 | SRR1368178 | GTEX | — | 0.811 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.180 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.160 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.130 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.090 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.090 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.050 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.030 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.030 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.010 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.010 | Inavolisib | — uncovered |